Initial experience with Temporary Implantable Nitinol Device (TIND) for benign prostatic hyperplasia

Abstract

Objectives:

To determine whether there is improvement in IPSS and uroflowmetry parameters in BPH patients who underwent TIND insertion and whether significant side effects were encountered in these patients

Patient and Methods:

All male patients with symptomatic BPH with prostate volume <75 mL were eligible for TIND insertion. Patient with a history of previous prostate surgery, non‐BPH causes of LUTS, post‐void residual >250 mL, impaired renal function, or active malignancy were excluded from the study. Demographic, baseline characteristics, pre‐insertion assessment and post‐insertion follow up were performed at 3, 6, 12 months. IPSS, uroflowmetry, sexual function, and adverse events were assessed on each follow up.

Results:

A total of 7 patients were inserted with TIND. Mean age of the patients were 69 years old. Mean pre‐operative Qmax was 9.7 mL/s. Mean Qmax improvement at 3 and 12 months were 4.0 mL/s and 4.2 mL/s, respectively. Mean IPSS improvement at 3 and 12 months were 11 pts and 4.7pts, respectively. One patient had deterioration of symptoms despite TIND and required TURP to be performed within 12 months of insertion.

Conclusions:

Initial experience with TIND for LUTS due to BPH is encouraging with satisfactory results within the first year of insertion.